{"id":48298,"date":"2022-09-13T13:02:01","date_gmt":"2022-09-13T11:02:01","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/metis-announces-pan-raf-inhibitor-license-agreement-with-voronoi\/"},"modified":"2022-09-13T13:02:01","modified_gmt":"2022-09-13T11:02:01","slug":"metis-announces-pan-raf-inhibitor-license-agreement-with-voronoi","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/metis-announces-pan-raf-inhibitor-license-agreement-with-voronoi\/","title":{"rendered":"METiS Announces Pan-RAF Inhibitor License Agreement with Voronoi"},"content":{"rendered":"
\n

CAMBRIDGE, Mass.–(BUSINESS WIRE)–METiS Therapeutics, a Boston-area company integrating drug discovery and delivery with AI and machine learning, today announced they have entered a license agreement with Voronoi, Inc., a Korean company focused on precision medicine. Under the terms of this license agreement, METiS will receive exclusive license to develop and commercialize Voronoi\u2019s pan-RAF inhibitor program worldwide. In exchange, Voronoi will receive up to $1.7 million in upfront cash and success-based near-term discovery milestones. Voronoi will also be eligible for success-based payment up to $480.5 million in development, regulatory and sales milestones and tiered royalties based on annual net sales.\n<\/p>\n

<\/a><\/p>\n

\n\u201cWe view this program as a potential best-in-class asset addressing high unmet clinical needs for Class II and Class III BRAF mutant cancer patients, particularly those with CNS metastasis,\u201d said Chris Lai, Co-Founder and CEO of METiS Therapeutics. \u201cWe see it as a compelling proof-of-concept opportunity for our AiTEM platform to improve compound pharmacokinetics and deliver a differentiated profile, including CNS penetration. In addition, we view this as a foundational asset for our oncology portfolio.\u201d\n<\/p>\n

\nBRAF is a protein kinase involved in cancer cell growth and BRAF mutations are the most common mutation found in tumor cells1<\/sup>. While several BRAF v600E inhibitors have been approved, this mutation only represents about 45% of total BRAF mutations, compared to Class II and III mutations which represent 55 percent of total BRAF mutations. This underscores the need for new therapeutic options in this space.\n<\/p>\n

\n\u201cWe developed our structurally distinguished type II pan-RAF inhibitor to address unmet medical needs, and this partnership brings us closer to our goal of delivering this candidate to patients,\u201d says Daekwon Kim, CEO of Voronoi. \u201cWe are excited to partner with METiS\u2019 seasoned team to continue on development of our pan-RAF inhibitor,\u201d added Daekwon.\n<\/p>\n

\nThis news follows METiS\u2019 announcement<\/a> that the company had joined the Roche Accelerator earlier this year. In December, METiS closed an $86 million Series A financing round. The company recently leased 14,000 square feet of mixed office and laboratory space at 101 Cambridgepark Drive in Cambridge, MA.\n<\/p>\n

\nAbout METiS<\/b>\n<\/p>\n

\nMETiS is a biotechnology company that aims to drive best-in-class therapies in a wide range of disease areas by integrating drug discovery and delivery with AI, machine learning, and quantum simulation. To learn more, please visit metistx.com<\/a>.\n<\/p>\n

\n1<\/sup> MEK and BRAF inhibitors plus other melanoma targeted therapies<\/i>. Memorial Sloan Kettering Cancer Center. (n.d.). Retrieved August 29, 2022, from https:\/\/www.mskcc.org\/cancer-care\/types\/melanoma\/treatment\/targeted-therapy-melanoma<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nCompany \/Partner:<\/b>
METiS Therapeutics
\n
(857) 225 6890
\n
partner@metistx.com<\/a> <\/span><\/b>\n<\/p>\n

\nMedia:<\/b>
MacDougall Advisors
\n
Lauren Arnold
\n
(781) 235-3060
\n
larnold@macdougall.bio<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CAMBRIDGE, Mass.–(BUSINESS WIRE)–METiS Therapeutics, a Boston-area company integrating drug discovery and delivery with AI and machine learning, today announced they have entered a license agreement with Voronoi, Inc., a Korean company focused on precision medicine. Under the terms of this license agreement, METiS will receive exclusive license to develop and commercialize Voronoi\u2019s pan-RAF inhibitor program … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48298","6":"format-standard","7":"category-industry"},"yoast_head":"\nMETiS Announces Pan-RAF Inhibitor License Agreement with Voronoi - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/metis-announces-pan-raf-inhibitor-license-agreement-with-voronoi\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"METiS Announces Pan-RAF Inhibitor License Agreement with Voronoi - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass.–(BUSINESS WIRE)–METiS Therapeutics, a Boston-area company integrating drug discovery and delivery with AI and machine learning, today announced they have entered a license agreement with Voronoi, Inc., a Korean company focused on precision medicine. Under the terms of this license agreement, METiS will receive exclusive license to develop and commercialize Voronoi\u2019s pan-RAF inhibitor program ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/metis-announces-pan-raf-inhibitor-license-agreement-with-voronoi\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-13T11:02:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220913005206\/en\/1568671\/21\/logo-metis-therapeutics.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metis-announces-pan-raf-inhibitor-license-agreement-with-voronoi\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metis-announces-pan-raf-inhibitor-license-agreement-with-voronoi\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"METiS Announces Pan-RAF Inhibitor License Agreement with Voronoi\",\"datePublished\":\"2022-09-13T11:02:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metis-announces-pan-raf-inhibitor-license-agreement-with-voronoi\\\/\"},\"wordCount\":432,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metis-announces-pan-raf-inhibitor-license-agreement-with-voronoi\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220913005206\\\/en\\\/1568671\\\/21\\\/logo-metis-therapeutics.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metis-announces-pan-raf-inhibitor-license-agreement-with-voronoi\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metis-announces-pan-raf-inhibitor-license-agreement-with-voronoi\\\/\",\"name\":\"METiS Announces Pan-RAF Inhibitor License Agreement with Voronoi - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metis-announces-pan-raf-inhibitor-license-agreement-with-voronoi\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metis-announces-pan-raf-inhibitor-license-agreement-with-voronoi\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220913005206\\\/en\\\/1568671\\\/21\\\/logo-metis-therapeutics.jpg\",\"datePublished\":\"2022-09-13T11:02:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metis-announces-pan-raf-inhibitor-license-agreement-with-voronoi\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metis-announces-pan-raf-inhibitor-license-agreement-with-voronoi\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metis-announces-pan-raf-inhibitor-license-agreement-with-voronoi\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220913005206\\\/en\\\/1568671\\\/21\\\/logo-metis-therapeutics.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220913005206\\\/en\\\/1568671\\\/21\\\/logo-metis-therapeutics.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/metis-announces-pan-raf-inhibitor-license-agreement-with-voronoi\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"METiS Announces Pan-RAF Inhibitor License Agreement with Voronoi\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"METiS Announces Pan-RAF Inhibitor License Agreement with Voronoi - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/metis-announces-pan-raf-inhibitor-license-agreement-with-voronoi\/","og_locale":"en_US","og_type":"article","og_title":"METiS Announces Pan-RAF Inhibitor License Agreement with Voronoi - Pharma Trend","og_description":"CAMBRIDGE, Mass.–(BUSINESS WIRE)–METiS Therapeutics, a Boston-area company integrating drug discovery and delivery with AI and machine learning, today announced they have entered a license agreement with Voronoi, Inc., a Korean company focused on precision medicine. Under the terms of this license agreement, METiS will receive exclusive license to develop and commercialize Voronoi\u2019s pan-RAF inhibitor program ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/metis-announces-pan-raf-inhibitor-license-agreement-with-voronoi\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-13T11:02:01+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220913005206\/en\/1568671\/21\/logo-metis-therapeutics.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/metis-announces-pan-raf-inhibitor-license-agreement-with-voronoi\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/metis-announces-pan-raf-inhibitor-license-agreement-with-voronoi\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"METiS Announces Pan-RAF Inhibitor License Agreement with Voronoi","datePublished":"2022-09-13T11:02:01+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/metis-announces-pan-raf-inhibitor-license-agreement-with-voronoi\/"},"wordCount":432,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/metis-announces-pan-raf-inhibitor-license-agreement-with-voronoi\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220913005206\/en\/1568671\/21\/logo-metis-therapeutics.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/metis-announces-pan-raf-inhibitor-license-agreement-with-voronoi\/","url":"https:\/\/pharma-trend.com\/en\/metis-announces-pan-raf-inhibitor-license-agreement-with-voronoi\/","name":"METiS Announces Pan-RAF Inhibitor License Agreement with Voronoi - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/metis-announces-pan-raf-inhibitor-license-agreement-with-voronoi\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/metis-announces-pan-raf-inhibitor-license-agreement-with-voronoi\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220913005206\/en\/1568671\/21\/logo-metis-therapeutics.jpg","datePublished":"2022-09-13T11:02:01+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/metis-announces-pan-raf-inhibitor-license-agreement-with-voronoi\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/metis-announces-pan-raf-inhibitor-license-agreement-with-voronoi\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/metis-announces-pan-raf-inhibitor-license-agreement-with-voronoi\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220913005206\/en\/1568671\/21\/logo-metis-therapeutics.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220913005206\/en\/1568671\/21\/logo-metis-therapeutics.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/metis-announces-pan-raf-inhibitor-license-agreement-with-voronoi\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"METiS Announces Pan-RAF Inhibitor License Agreement with Voronoi"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48298","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48298"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48298\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48298"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48298"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48298"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}